Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.05 USD
Change Today -0.0015 / -2.80%
Volume 3.5K
As of 9:30 AM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

nuo therapeutics inc (NUOT) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/12/14 - $0.48
52 Week Low
08/17/15 - $0.03
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NUO THERAPEUTICS INC (NUOT)

Related News

No related news articles were found.

nuo therapeutics inc (NUOT) Related Businessweek News

No Related Businessweek News Found

nuo therapeutics inc (NUOT) Details

Nuo Therapeutics, Inc., a biomedical company, provides biodynamic therapies for wound care in the United States and internationally. Its flagship product is Aurix system, a biodynamic hematogel that harnesses a patient's innate regenerative abilities for the management of various wounds. The company also offers Angel Concentrated Platelet Rich Plasma System, a multi-functional cell separation device, which produces concentrated platelet rich plasma for use in the operating room and clinic, as well as in a range of orthopedic and cardiovascular indications; ancillary products, such as phlebotomy and applicator supplies; and activAT, which produces autologous thrombin serum from platelet poor plasma. In addition, the company develops Bright Cell technology platform, which is a novel approach to cell-based regenerative medicine. Nuo Therapeutics, Inc. sells its products through direct sales representatives and distributors. The company was formerly known as Cytomedix, Inc. and changed its name to Nuo Therapeutics, Inc. in November 2014. Nuo Therapeutics, Inc. was founded in 1987 and is based in Gaithersburg, Maryland.

46 Employees
Last Reported Date: 05/13/15
Founded in 1987

nuo therapeutics inc (NUOT) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $225.0K
Compensation as of Fiscal Year 2014.

nuo therapeutics inc (NUOT) Key Developments

Nuo Therapeutics Provides Updates on VA Commercialization Efforts

Nuo Therapeutics, Inc. announced several updates related to its focus on making the company's chronic wound care solution, Aurix™, broadly available to facilities within the Department of Veterans Affairs (VA) Healthcare System. Aurix is now available on the Federal Supply Schedule. Aurix to be featured in Product Showcase at 2015 PVA Summit + Expo. Nuo bolsters VA-dedicated sales team. The modification is effective as of August 15, 2015, and is added to the company's existing FSS contract (V797P-4001B), issued by the VA National Acquisition Center. Additionally, Nuo Therapeutics will continue its support of the Paralyzed Veterans of America (PVA) by participating in the 5th Annual PVA Summit + Expo to be held on September 1 - 3 in Jacksonville, FL.

Nuo Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Nuo Therapeutics, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenue of $2,895,231 against $9,822,490 a year ago. Loss from operations was $4,437,017 against $242 a year ago. Loss before provision for income taxes was $865,342 against $11,315,993 a year ago. Net loss was $870,238 against $11,320,638 a year ago. Basic and diluted loss per share was $0.01 against $0.09 a year ago. The year-over-year increase in total Revenue was primarily related to increased sales and royalties associated with the company's Angel product line. Second quarter 2015 net loss included an unrealized non-cash gain related to the change in fair value of derivative liabilities totaling $4.5 million. This compares to an unrealized non-cash loss of $0.9 million in the second quarter of 2014. For the six months, the company reported total revenue of $7,732,358 against $4,172,033 a year ago. Loss from operations was $7,807,786 against $14,472,650 a year ago. Income before provision for income taxes was $3,246,530 against loss of $16,944,261 a year ago. Net income was $3,236,763 against loss of $16,953,551 a year ago. Basic and diluted earnings per share were $0.01 against basic and diluted loss per share of $0.15 a year ago.

Nuo Therapeutics, Inc. to Report Q2, 2015 Results on Aug 13, 2015

Nuo Therapeutics, Inc. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Aug 13, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NUOT:US $0.05 USD -0.0015

NUOT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Athersys Inc $1.14 USD +0.0092
Cesca Therapeutics Inc $0.62 USD -0.03
Cytori Therapeutics Inc $0.37 USD 0.00
International Stem Cell Corp $3.59 USD +0.01
StemCells Inc $0.50 USD -0.0172
View Industry Companies

Industry Analysis


Industry Average

Valuation NUOT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.6x
Price/Book 0.3x
Price/Cash Flow 5.0x
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NUO THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at